Ebola virus EBOV (subtype Zaire, strain Mayinga 1976) Glycoprotein / GP Protein (His Tag)


Ebola virus EBOV (subtype Zaire, strain Mayinga 1976) Glycoprotein / GP Protein (His Tag): Product Information

> 95% as determined by SDS-PAGE
< 1.0 EU per μg protein as determined by the LAL method.
Testing in progress
Protein Construction
A DNA sequence encoding the Zaire ebolavirus (strain Mayinga 1976) GP (AAC54887.1) (Met1-Gln650) was expressed with a polyhistidine tag at the C-terminus.
Expressed Host
Baculovirus-Insect Cells
Predicted N Terminal
Molecule Mass
The recombinant Zaire ebolavirus (strain Mayinga 1976) GP consists 629 amino acids and predicts a molecular mass of 69.3 kDa.
Lyophilized from sterile 20mM Tris,500mM NaCl,10% glycerol, pH 8.0.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Ebola virus EBOV (subtype Zaire, strain Mayinga 1976) Glycoprotein / GP Protein (His Tag): Images

Ebola virus Glycoprotein Background Information

The fourth gene of the EBOV genome encodes a 16-kDa envelope-attached glycoprotein (GP) and a 11 kDa secreted glycoprotein (sGP). Both GP and sGP have an identical 295-residue N-terminus, however, they have different C-terminal sequences. Recently, great attention has been paid to GP for vaccines design and entry inhibitors isolation. GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . The GP1 subunit contains a mucin domain and a receptor-binding domain (RBD); the GP2 subunit has a fusion peptide, a helical heptad-repeat (HR) region, a transmembrane (TM) domain, and a 4-residue cytoplasmic tail. The RBD of GP1 mediates the interaction of EBOV with cellular receptor (e.g. DC-SIGN/LSIGN, TIM-1, hMGL, NPC1, β-integrins, folate receptor-α, and Tyro3 family receptors), of which TIM1 and NPC1 are essential for EBOV entry; the mucin domain having N- and O-linked glycans enhances the viral attachment to cellular hMGL, and participates in shielding key neutralization epitopes, which helps the virus evades immune elimination. There are large conformation changes of GP2 during membrane fusion, which enhance the insertion of fusion loop into cellular membrane and facilitate the release of viral nucleocapsid core to cytoplasm.
  • Volchkov VE, et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A. 1998 May 12;95(10):5762-7.
  • Lee JE, et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008 Jul 10;454(7201):177-82. doi: 10.1038/nature07082.
  • Hood CL, et al. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol. 2010 Mar;84(6):2972-82. doi: 10.1128/JVI.02151-09.
  • Cook JD and Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 2013 May;9(5):e1003258. doi: 10.1371/journal.ppat.1003258.
  • Miller EH and Chandran K. Filovirus entry into cells - new insights. Curr Opin Virol. 2012 Apr;2(2):206-14. doi: 10.1016/j.coviro.2012.02.015.

EBOV Ebola virus Glycoprotein Proteins

  • Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection
    Liu, Q;Fan, C;Li, Q;Zhou, S;Huang, W;Wang, L;Sun, C;Wang, M;Wu, X;Ma, J;Li, B;Xie, L;Wang, Y;
    Sci Rep
  • In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model
    Patel, A;Park, D;Davis, C;Smith, T;Leung, A;Tierney, K;Bryan, A;Davidson, E;Yu, X;Racine, T;Reed, C;Gorman, M;Wise, M;Elliott, S;Esquivel, R;Yan, J;Chen, J;Muthumani, K;Doranz, B;Saphire, E;Crowe, J;Broderick, K;Kobinger, G;He, S;Qiu, X;Kobasa, D;Humeau, L;Sardesai, N;Ahmed, R;Weiner, D;
    Cell Reports
  • Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection
    Shcheblyakov, D;Esmagambetov, I;Simakin, P;Kostina, L;Kozlov, A;Tsibezov, V;Grebennikova, T;Chifanov, D;Rumyantseva, I;Boyarskaya, N;Sizikova, T;Shagarova, N;Andrus, А;Shatohina, I;Syromyatnikova, S;Kovalchuk, A;Pantyukhov, V;Borisevich, S;Zubkova, O;Tuhvatulin, A;Logunov, D;Naroditsky, B;Gintsburg, A;
    Antiviral Res.
    ELISA and Octet
  • Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design
    Khurana, S;Ravichandran, S;Hahn, M;Coyle, EM;Stonier, SW;Zak, SE;Kindrachuk, J;Davey, RT;Dye, JM;Chertow, DS;
    Cell Host Microbe
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.